
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc. has demonstrated a robust expansion in gross margins, growing from the low 40s to approximately 60%, primarily driven by the increased clinical volume and higher average selling prices (ASPs) of key tests like Signatera. The company's revenue has nearly sextupled since 2019, indicating a strong financial foundation that supports further growth, especially in the sizeable $30 billion cancer screening total addressable market (TAM). With a growing Medicare Advantage reimbursement rate—from around 20% in the second half of 2023 to mid-to-high 60% by the end of 2024—alongside the introduction of new tests and enhanced market presence, Natera is well-positioned for sustained revenue growth and market leadership.
Bears say
Natera Inc is facing a challenging outlook due to weaker-than-expected fourth-quarter volumes primarily linked to disruptions from electronic medical record (EMR) integration and seasonal factors, which have raised concerns about its near-term revenue growth. Furthermore, the company's 2025 revenue guidance falls approximately $28.3 million below consensus, reflecting potential decreases in reimbursement for its products from payors, coupled with ongoing margin erosion due to pricing pressures in a competitive landscape. Additionally, any delays in clinical trial readouts or necessary reevaluations of product launch strategies could further hinder Natera's long-term revenue growth and profitability trajectory.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares